Patent intelligence · US
US 2023174645
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
Patent details — US 2023174645
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 8, 2023
- Expiration
- Jun 3, 2043
- Applicant
- DISC MEDICINE INC [US]
- CPC classes
- A61P 35/ 00 A I, A61P/3500, A61P/700, A61P/706
Quick answer
US 2023174645 (ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS) is held by DISC MEDICINE INC [US]. Status: granted. Granted Jun 8, 2023. Expires Jun 3, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DISC MEDICINE INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P 35/ 00 A I, A61P/3500, A61P/700, A61P/706
More from DISC MEDICINE INC [US]
Related pharmaceutical patents in our USPTO index.
-
WO 2024243450
MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET
granted -
CA 3266054
COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE
granted -
CA 3259391
POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1
granted -
CA 3245150
COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE
granted -
CA 3235096
METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE
granted -
CA 3207179
METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE
granted -
US 2022169620
SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS
granted
Frequently asked questions
What is US patent 2023174645?
US 2023174645 (ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS) is held by DISC MEDICINE INC [US]. Status: granted. Granted Jun 8, 2023. Expires Jun 3, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2023174645?
DISC MEDICINE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does US 2023174645 expire?
Our index shows an expiration date of Jun 3, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.